Dr. Hongyang Lu 卢红阳
Chief Physician
Department of Medical Oncology for Thoracic Tumors, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical oncology for thoracic tumors, including chemotherapy and targeted therapy for lung cancer, breast cancer, malignant lymphoma, and gastrointestinal tumors.
Dr. Lu holds a medical doctorate and has worked in the Department of Medical Oncology at Zhejiang Cancer Hospital since July 2002. A master’s supervisor and peer reviewer for the National Natural Science Foundation, Dr. Lu leads research on small cell lung cancer, hosting national and provincial foundation projects. Dr. Lu has published over 40 academic papers and participated in multiple clinical trials.
Professional roles
- Secretary and Vice Chair of the Youth Committee, Lung Cancer Professional Committee, Zhejiang Anti-Cancer Association
- Youth Member, Tumor Chemotherapy Professional Committee, Zhejiang Anti-Cancer Association
- Youth Member, Tumor Marker Professional Committee, Zhejiang Anti-Cancer Association
- Member, Clinical Immunology Professional Committee, Zhejiang Immunological Society
Name order: in Chinese the family name comes first (Lu Hongyang). Papers usually list the name as Hongyang Lu or Lu H.
Selected publications
79 papers on PubMed matched by name and affiliation; 52 as first or senior author since 2016. Most recent first- or senior-author papers:
- Ther Adv Med Oncol, 2026 (senior author): The efficacy of targeted therapy in ALK-positive non-small-cell lung cancer patients and analysis of MET/PD-L1 expression status. PubMed 42369729
- Eur Radiol, 2026 (senior author): Malignant pleural mesothelioma classification and survival prediction with CT imaging using ResNet. PubMed 41168494
- Ann Med, 2025 (senior author): The clinicopathologic characteristics and tumor immune microenvironment of pulmonary enteric adenocarcinoma. PubMed 40560796
- Ann Med, 2025 (senior author): Clinical outcomes of EGFR-TKI in advanced lung squamous cell carcinoma and EGFR-TKI remodel tumor immune microenvironment. PubMed 40193238
- Invest New Drugs, 2025 (senior author): The analysis of molecular classification of pulmonary neuroendocrine tumors and relationship between YAP1 and efficacy. PubMed 39786663
- Ther Adv Med Oncol, 2024 (senior author): Bone metastasis in non-small-cell lung cancer: genomic characterization and exploration of potential targets. PubMed 38510678
- J Cancer Res Clin Oncol, 2024 (senior author): Primary pulmonary myxoid sarcoma with EWSR1::CREB1 fusion: a literature review. PubMed 38421462
- Diagn Pathol, 2024 (senior author): Pulmonary salivary gland tumor-hyalinizing clear cell carcinoma: a literature review. PubMed 38389101
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion